Your session is about to expire
What is Rowasa
MesalazineThe Generic name of this drug
Treatment SummaryMesalazine is an anti-inflammatory medication related to aspirin and other non-steroidal anti-inflammatory drugs. It is used to treat and maintain remission for ulcerative colitis. Over the years, researchers have developed medications that contain mesalazine in more stable forms, such as Asacol and Pentasa. Recent studies have also looked into the potential of mesalazine to reduce inflammation and possibly lower the risk of colorectal cancer in people with ulcerative colitis.
Rowasais the brand name
Rowasa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Rowasa
Mesalazine
1988
107
Approved as Treatment by the FDA
Mesalazine, otherwise called Rowasa, is approved by the FDA for 1 uses which include Crohn Disease .Crohn Disease
Effectiveness
How Rowasa Affects PatientsMesalazine is one of two components in sulphasalazine, a medication used to treat ulcerative colitis. It is thought to reduce inflammation by blocking the production of certain substances that cause inflammation, like prostaglandins and leukotrienes, and also by neutralizing free radicals. Studies have shown that mesalazine given orally or directly into the abdomen can help reduce inflammation in mice and guinea pigs with colitis.
How Rowasa works in the bodyMesalazine works to reduce inflammation in the colon. It does this by blocking certain pathways that increase inflammation, such as the production of prostaglandins and leukotrienes. It also works by inhibiting Nuclear Factor kappa B, which helps reduce pro-inflammatory cytokines. Mesalazine also has the potential to activate PPAR gamma receptors and inhibit iNOS, which helps lower inflammation in the intestine. Finally, mesalazine also decreases leukocyte chemotaxis, decreases cytokines and leukotrienes, and scavenges for free radicals, helping reduce inflammation overall.
When to interrupt dosage
The measure of Rowasa is contingent upon the diagnosed condition. The quantity of dosage shifts, as per the method of delivery stated in the table below.Condition
Dosage
Administration
Proctitis
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
Oral, Tablet, delayed release - Oral, , Tablet, delayed release, Capsule, delayed release - Oral, Capsule, delayed release, Rectal, Enema, Enema - Rectal, Kit, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Rectal, Suppository, Suppository - Rectal, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Enema; Liquid, Enema; Liquid - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal
Proctocolitis
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
Oral, Tablet, delayed release - Oral, , Tablet, delayed release, Capsule, delayed release - Oral, Capsule, delayed release, Rectal, Enema, Enema - Rectal, Kit, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Rectal, Suppository, Suppository - Rectal, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Enema; Liquid, Enema; Liquid - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal
Colitis, Ulcerative
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
Oral, Tablet, delayed release - Oral, , Tablet, delayed release, Capsule, delayed release - Oral, Capsule, delayed release, Rectal, Enema, Enema - Rectal, Kit, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Rectal, Suppository, Suppository - Rectal, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Enema; Liquid, Enema; Liquid - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal
Ulcerative Colitis
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
Oral, Tablet, delayed release - Oral, , Tablet, delayed release, Capsule, delayed release - Oral, Capsule, delayed release, Rectal, Enema, Enema - Rectal, Kit, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Rectal, Suppository, Suppository - Rectal, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Enema; Liquid, Enema; Liquid - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal
Crohn Disease
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
Oral, Tablet, delayed release - Oral, , Tablet, delayed release, Capsule, delayed release - Oral, Capsule, delayed release, Rectal, Enema, Enema - Rectal, Kit, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Rectal, Suppository, Suppository - Rectal, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Enema; Liquid, Enema; Liquid - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal
Warnings
Rowasa has eight contraindications. It should not be administered when suffering from any of the afflictions in the following table.Rowasa ContraindicationsCondition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Mesalazine may interact with Pulse Frequency
Common Rowasa Drug Interactions
Drug Name
Risk Level
Description
Macimorelin
Major
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Mesalazine.
Methotrexate
Major
The serum concentration of Methotrexate can be increased when it is combined with Mesalazine.
Mifamurtide
Major
The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Mesalazine.
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Neomycin.
Omacetaxine mepesuccinate
Major
The risk or severity of bleeding can be increased when Mesalazine is combined with Omacetaxine mepesuccinate.
Rowasa Toxicity & Overdose RiskIn rat studies, no increase in cancer risk was found with up to 1.7 times the recommended human dose of mesalazine. The drug was also not found to be mutagenic. No fertility or reproductive problems were reported in male or female rats at this dose. Symptoms of an overdose include nausea, vomiting, breathing difficulties, ringing in the ears, and confusion. In more severe cases, electrolyte and pH levels can become unbalanced and other organs can be affected. There is no specific antidote; however, conventional treatments for salicylate toxicity can help reduce the effects of an overdose. People with kidney disease or a history
Rowasa Novel Uses: Which Conditions Have a Clinical Trial Featuring Rowasa?
At present, 96 active studies are assessing the utility of Rowasa in the management of Ulcerative Colitis.Condition
Clinical Trials
Trial Phases
Proctitis
0 Actively Recruiting
Crohn Disease
0 Actively Recruiting
Proctocolitis
0 Actively Recruiting
Colitis, Ulcerative
0 Actively Recruiting
Ulcerative Colitis
0 Actively Recruiting
Rowasa Reviews: What are patients saying about Rowasa?
5Patient Review
7/21/2010 Ulcerative colitis is a tough condition to deal with, but this medication has been incredibly effective for me and my family. We've all been using it for years with great results.
5Patient Review
12/18/2012 This has been my go-to twice now for flares of ulcerative colitis. Within a week, the blood and mucous stopped--and I experienced zero side effects.
5Patient Review
10/20/2016 Though it's not the most pleasant experience, this medication offers quick and effective relief whenever I'm in pain.
3.3Patient Review
1/21/2009 Rowasa is effective at stopping flares, but my doctor wants me to use it EVERY night. I'd rather not enema myself every night, so we'll see how the Asacol goes.
3.3Patient Review
6/21/2008 Rowasa can sometimes be difficult to hold in for the entire night.
2Patient Review
5/24/2010 I've used this medication in the past, but it seems to have made my symptoms worse rather than better. I stopped taking it a few days ago and have been feeling much better since then.
Patient Q&A Section about rowasa
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.How is Rowasa taken?
"Insert the suppository gently into the rectum with your finger, pointed end first. You may want to use a small amount of lubricating gel on the tip of the suppository. Stay lying down for a few minutes. Try not to have a bowel movement for 1 to 3 hours, so the medicine can work."
Answered by AI
What is Rowasa used for?
"Mesalamine is a drug that is used to treat ulcerative colitis, which is an inflammatory bowel condition. The drug is available in the form of an enema, which is designed to lower swelling and inflammation in the colon. However, the drug can sometimes cause allergic reactions."
Answered by AI
How does a Rowasa enema work?
"Mesalamine is an aminosalicylate anti-inflammatory drug which is thought to work by hindering the creation of certain natural chemicals that can lead to pain and swelling."
Answered by AI
How quickly does Rowasa work?
"It usually takes 3 to 6 weeks to see the full effect of ROWASA® (mesalamine) Rectal Suspension Enema, although some people may see a difference within 3 to 21 days."
Answered by AI